These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 25734149)

  • 1. The successful application of a national peer advisory committee for physicians who provide salvage regimens to heavily antiretroviral-experienced patients in mexican human immunodeficiency virus clinics.
    Calva JJ; Sierra-Madero J; Soto-Ramírez LE; Aguilar-Salinas P
    Open Forum Infect Dis; 2014 Sep; 1(2):ofu081. PubMed ID: 25734149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
    Hazra R; Gafni RI; Maldarelli F; Balis FM; Tullio AN; DeCarlo E; Worrell CJ; Steinberg SM; Flaherty J; Yale K; Kearney BP; Zeichner SL
    Pediatrics; 2005 Dec; 116(6):e846-54. PubMed ID: 16291735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.
    Deeks SG; Barbour JD; Grant RM; Martin JN
    AIDS; 2002 Jan; 16(2):201-7. PubMed ID: 11807304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen.
    Gandhi T; Nagappan V; Cinti S; Wei W; Kazanjian P
    Clin Infect Dis; 2007 Oct; 45(8):1085-92. PubMed ID: 17879930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis-Maraviroc Effectiveness in HIV-1 Subtype C.
    Pujari S; Gaikwad S; Bele V; Joshi K; Dabhade D
    J Int Assoc Provid AIDS Care; 2018; 17():2325958218759211. PubMed ID: 29473485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
    Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
    Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
    Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.
    Briz V; León-Leal JA; Palladino C; Moreno-Perez D; de Ory SJ; De José MI; González-Tomé MI; Martín CG; Pocheville I; Ramos JT; Leal M; Muñoz-Fernández MÁ
    Pediatr Infect Dis J; 2012 Mar; 31(3):273-7. PubMed ID: 22330165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen.
    Cohen C
    HIV Clin Trials; 2009; 10(2):116-24. PubMed ID: 19487182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095.
    Li L; Eron JJ; Ribaudo H; Gulick RM; Johnson BA
    J Am Stat Assoc; 2012; 107(498):542-554. PubMed ID: 23329858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
    Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
    Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam.
    Cuong DD; Sönnerborg A; Van Tam V; El-Khatib Z; Santacatterina M; Marrone G; Chuc NT; Diwan V; Thorson A; Le NK; An PN; Larsson M
    BMC Infect Dis; 2016 Dec; 16(1):759. PubMed ID: 27986077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.
    Deeks SG; Hecht FM; Swanson M; Elbeik T; Loftus R; Cohen PT; Grant RM
    AIDS; 1999 Apr; 13(6):F35-43. PubMed ID: 10397555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of patients with low-level HIV viremia on antiretroviral therapy.
    Lo Re V; Gasink L; Kostman JR; Leonard D; Gross R
    AIDS Patient Care STDS; 2004 Aug; 18(8):436-42. PubMed ID: 15321015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
    Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT;
    J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.